Initiation and Up-Titration of Guideline-Based Medications in Hospitalized Acute Heart Failure Patients - A Report From the West Tokyo Heart Failure Registry.

Acute heart failure Guideline-directed medical therapy Up-titration

Journal

Circulation journal : official journal of the Japanese Circulation Society
ISSN: 1347-4820
Titre abrégé: Circ J
Pays: Japan
ID NLM: 101137683

Informations de publication

Date de publication:
31 Oct 2023
Historique:
medline: 2 11 2023
pubmed: 2 11 2023
entrez: 1 11 2023
Statut: aheadofprint

Résumé

Despite recommendations from clinical practice guidelines to initiate and titrate guideline-directed medical therapy (GDMT) during their hospitalization, patients with acute heart failure (AHF) are frequently undertreated. In this study we aimed to clarify GDMT implementation and titration rates, as well as the long-term outcomes, in hospitalized AHF patients.Methods and Results: Among 3,164 consecutive hospitalized AHF patients included in a Japanese multicenter registry, 1,400 (44.2%) with ejection fraction ≤40% were analyzed. We assessed GDMT dosage (β-blockers, renin-angiotensin inhibitors, and mineralocorticoid-receptor antagonists) at admission and discharge, examined the contributing factors for up-titration, and evaluated associations between drug initiation/up-titration and 1-year post-discharge all-cause death and rehospitalization for HF via propensity score matching. The mean age of the patients was 71.5 years and 30.7% were female. Overall, 1,051 patients (75.0%) were deemed eligible for GDMT, based on their baseline vital signs, renal function, and electrolyte values. At discharge, only 180 patients (17.1%) received GDMT agents up-titrated to >50% of the maximum titrated dose. Up-titration was associated with a lower risk of 1-year clinical outcomes (adjusted hazard ratio: 0.58, 95% confidence interval: 0.35-0.96). Younger age and higher body mass index were significant predictors of drug up-titration. Significant evidence-practice gaps in the use and dose of GDMT remain. Considering the associated favorable outcomes, further efforts to improve its implementation seem crucial.

Sections du résumé

BACKGROUND BACKGROUND
Despite recommendations from clinical practice guidelines to initiate and titrate guideline-directed medical therapy (GDMT) during their hospitalization, patients with acute heart failure (AHF) are frequently undertreated. In this study we aimed to clarify GDMT implementation and titration rates, as well as the long-term outcomes, in hospitalized AHF patients.Methods and Results: Among 3,164 consecutive hospitalized AHF patients included in a Japanese multicenter registry, 1,400 (44.2%) with ejection fraction ≤40% were analyzed. We assessed GDMT dosage (β-blockers, renin-angiotensin inhibitors, and mineralocorticoid-receptor antagonists) at admission and discharge, examined the contributing factors for up-titration, and evaluated associations between drug initiation/up-titration and 1-year post-discharge all-cause death and rehospitalization for HF via propensity score matching. The mean age of the patients was 71.5 years and 30.7% were female. Overall, 1,051 patients (75.0%) were deemed eligible for GDMT, based on their baseline vital signs, renal function, and electrolyte values. At discharge, only 180 patients (17.1%) received GDMT agents up-titrated to >50% of the maximum titrated dose. Up-titration was associated with a lower risk of 1-year clinical outcomes (adjusted hazard ratio: 0.58, 95% confidence interval: 0.35-0.96). Younger age and higher body mass index were significant predictors of drug up-titration.
CONCLUSIONS CONCLUSIONS
Significant evidence-practice gaps in the use and dose of GDMT remain. Considering the associated favorable outcomes, further efforts to improve its implementation seem crucial.

Identifiants

pubmed: 37914282
doi: 10.1253/circj.CJ-23-0356
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Takanori Ohata (T)

Department of Cardiology, Keio University School of Medicine.

Nozomi Niimi (N)

General Internal Medicine, National Hospital Organization Tokyo Medical Center.

Yasuyuki Shiraishi (Y)

Department of Cardiology, Keio University School of Medicine.

Fumiko Nakatsu (F)

Medical Affairs Division, Novartis Pharma K.K.

Ichiro Umemura (I)

Medical Affairs Division, Novartis Pharma K.K.

Takashi Kohno (T)

Department of Cardiovascular Medicine, Kyorin University Faculty of Medicine.

Yuji Nagatomo (Y)

Department of Cardiology, National Defense Medical College Hospital.

Makoto Takei (M)

Department of Cardiology, Saiseikai Central Hospital.

Tomohiko Ono (T)

Department of Cardiology, National Hospital Organization Saitama National Hospital.

Munehisa Sakamoto (M)

Department of Cardiology, National Hospital Organization Tokyo Medical Center.

Shintaro Nakano (S)

Department of Cardiology, Saitama Medical University International Medical Center.

Keiichi Fukuda (K)

Department of Cardiology, Keio University School of Medicine.

Shun Kohsaka (S)

Department of Cardiology, Keio University School of Medicine.

Tsutomu Yoshikawa (T)

Department of Cardiology, Sakakibara Heart Institute.

Classifications MeSH